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ARTICLE OPEN
Targeted kinase inhibition relieves slowness and tremor in a
Drosophila model of LRRK2 Parkinson’s disease
Amy C. Cording1, Nicolas Shiaelis1, Stavroula Petridi1, C. Adam Middleton1, Laurence G. Wilson 2 and Christopher J. H. Elliott 1
In a number of Drosophila models of genetic Parkinson’s disease (PD) flies climb more slowly than wild-type controls. However, this
assay does not distinguish effects of PD-related genes on gravity sensation, “arousal”, central pattern generation of leg movements,
or muscle. To address this problem, we have developed an assay for the fly proboscis extension response (PER). This is attractive
because the PER has a simple, well-identified reflex neural circuit, in which sucrose sensing neurons activate a pair of “command
interneurons”, and thence motoneurons whose activity contracts the proboscis muscle. This circuit is modulated by a single
dopaminergic neuron (TH-VUM). We find that expressing either the G2019S or I2020T (but not R1441C, or kinase dead) forms of
human LRRK2 in dopaminergic neurons reduces the percentage of flies that initially respond to sucrose stimulation. This is rescued
fully by feeding L-DOPA and partially by feeding kinase inhibitors, targeted to LRRK2 (LRRK2-IN-1 and BMPPB-32). High-speed video
shows that G2019S expression in dopaminergic neurons slows the speed of proboscis extension, makes its duration more variable,
and increases the tremor. Testing subsets of dopaminergic neurons suggests that the single TH-VUM neuron is likely most
important in this phenotype. We conclude the Drosophila PER provides an excellent model of LRRK2 motor deficits showing
bradykinesia, akinesia, hypokinesia, and increased tremor, with the possibility to localize changes in neural signaling.
npj Parkinson' s Disease  (2017) 3:34 ; doi:10.1038/s41531-017-0036-y
INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative
condition characterized by pathological loss of dopaminergic
neurons in the substantia nigra. The reduction in dopamine in the
projections to the striatum leads to a range of motor disorders,
characterized by bradykinesia (slower movements), hypokinesia (a
reduction in the amplitude of movements), akinesia (absence of
movement altogether), and tremor.
Although the cause of the majority of PD is unknown, a small
proportion is inherited (see, for a review, ref. 1) with the most
common genetic form being due to mutations in LRRK2 (Leucine-
Rich Repeat Kinase 2).
This gene is translated into a large, multi-domain protein, and
the pathogenic mutations include G2019S and I2020T,2 in which
the kinase activity is increased,3 and R1441C, a mutation in which
the GTPase activity is thought to be reduced.4
The excellent genetic toolkit provided by Drosophila led to the
creation of fly models of PD. These reflect many features of the
disease (loss of dopaminergic neurons, reduced movement,
mitochondrial abnormalities, oxidative stress. and visual defi-
cits).5,6 Many labs have adopted the fly negative geotaxis assay
(sometimes called the “startle response assay”) as their measure of
movement.7–9 In this, the speed at which flies walk up a glass
cylinder in response to a sharp tap is recorded. Although PD-
mimic flies have reduced movement, it is hard to specify exactly
where the changes are taking place (response to the startle
stimulus or gravity, or effects on the central pattern generator or
motor neurons or changes directly affecting the leg muscles
themselves). This assay also fails to discriminate between the
different possible movement defects (akinesia, hypokinesia, and
bradykinesia). We suggest the requirement for another, simpler
assay system.
This is reinforced by the difficulty of determining which of the
~125 dopaminergic neurons in the fly CNS10,11 are important in
the negative geotaxis response. Although dopaminergic innerva-
tion of the mushroom body by 15 “PAM” neurons plays a major
role in this negative geotaxis response,12 the subsequent neuronal
pathway is unclear. Further, manipulations of PD-related trans-
genes often lead to the loss of a relatively small proportion of
dopaminergic neurons, with many clusters remaining unaffected.
For example, with the LRRK2-G2019S mutation, the protocerebral
posterior medial (PPM) cluster dropped from 14 to 12 dopami-
nergic neurons but the protocerebral anterior lateral (PAL) cluster
remained unaffected.13 Throughout the literature, the multiple
processes involved in slowed negative geotaxis combined with
the observed small loss of dopaminergic neurons act to obscure
the functional relationship. To progress, we need to link a precise
measurement of movement with the physiology of a few specific
dopaminergic neurons.
An exciting solution to this problem is provided by the
discovery that a single dopaminergic neuron strongly modulates
the fly proboscis extension response (PER).14
As a fly walks into a solution containing sucrose, the Gr5a
chemosensory cells on its front legs are activated (Fig. 1, step 1).
Their axons project to the sub-esophageal zone of the CNS (SEZ;
the part signaling the taste response; Fig. 1, step 2). Within the
SEZ, the chemosensory inputs activate the interneuronal path-
way,15 leading to the pharyngeal E49 motoneurons, whose action
potentials elicit contraction of the M9 muscle (Fig. 1, step 3). This
well characterized neuronal pathway results in the reflex extrusion
of the proboscis towards the food (Fig. 1, step 4), allowing the fly
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to ingest the solution. Although the sensory and motor steps in
this pathway have been well defined (see for a review ref. 16 or
ref. 17), the interneuronal steps mostly remain to be described.
One well-defined neuron that modulates the PER is TH-VUM, a
single, unpaired neuron in the SEZ, which makes output synapses
onto the sense cells and interneurons14,18,19 (Fig. 1). Strong activity
in the TH-VUM leads to contraction of the proboscis muscle,
blocking the output of the TH-VUM reduces the probability of a
sucrose-induced PER. The frequency of action potentials in the TH-
VUM correlates with the length of starvation.14 Interestingly, the
TH-VUM fires steadily in a way reminiscent of mammalian
substantia nigra dopaminergic neurons.20
We have now found that expression of LRRK2-G2019S, the most
common cause of genetic PD, in dopamine neurons results in a
reduced PER, with bradykinesia, akinesia, and tremor, and that this
is rescued by L-DOPA or by kinase inhibitors targeted at LRRK2.
RESULTS
Upregulation of LRRK2 kinase activity in dopaminergic neurons
causes akinesia
In order to test the neuronal specificity of the PD-related mutation
LRRK2-G2019S, we first expressed this in each of the components
of the PER reflex pathway, recording the proportion of a
population of starved flies that extended their proboscis in
response to a moderate (100 mM) sugar stimulus (Fig. 2a, b).
Strikingly, when we expressed LRRK2-G2019S in the dopaminergic
neurons with TH-GAL4 (tyrosine hydoxylase GAL4), the proportion
of young flies responding was about half that of control
genotypes (no transgene expressed, χ2-post-hoc test, p < 0.001;
from 76–35%; Fig. 2a). The same result was seen in a second
sample, where the proportion of TH>G2019S flies responding was
also less than half that of the wild type (Fig. 2b). In contrast, there
was no effect of G2019S when driven in all neurons (nSyb-GAL4, p
= 0.17), or in just the sensory neurons (Gr5a-GAL4, p = 0.11), or
solely in proboscis motoneurons (E49-GAL4, p = 0.21).
In order to establish if this was specific for the G2019S mutation,
we also tested a second PD-related mutation in which kinase
activity is increased (I2020T), a mutation in the GTPase domain
(R1441C), a kinase dead form (LRRK2-G2019S-K1906M), and the
normal human form (hLRRK2). Of these, only dopaminergic
expression of I2020T had any specific effect, reducing the
proportion of flies that responded from 61 to 35 % (χ2-post-hoc
test, p < 0.001; Fig. 2b). We did note a general reduction on all flies
containing the hLRRK2 (Fig. 2a, b), due perhaps to the increased
expression levels of this gene (Fig. 2c). In turn, the lack of effect of
TH>R1441Cmight be due to the weaker expression (Fig. 2c), based
on our hypothesis that the impact of any one LRRK2 mutant on
PER is correlated with the level of LRRK2 protein production in the
dopaminergic neurons.
We tested a second set of independently generated LRRK2
transgenic flies,21 and found the same: only 36% of TH>G2019S
flies responded compared with 52% of TH>hLRRK2 and 61% of
TH/+ (χ2-post-hoc test, G2019S vs hLRRK2, p = 0.04; G2019S vs wild
type, p = 0.0034).
To determine if the PER response was age dependent, we
tested flies from 3 days to over 18 days, and found none of the
genotypes showed any age dependent change (Fig. 2b). Dopa-
minergic expression of G2019S or I2020T reduced the proportion
of flies responding to the sucrose stimulus at all ages.
We found no effect of genotype on mass at 20 days (non-
transgene control vs TH>hLRRK2 vs TH>G2019S, F2,26 df = 0.003, p
= 0.99), suggesting the reduced frequency of PER seen in starved
flies was not preventing them from increasing their mass when
provided with food ad libitum. However, by 28 days, only 57% of
flies were alive, with increased mortality in each of the TH>hLRRK2,
TH>G2019S, and TH>I2020T compared to the TH/+ control (χ2-
post-hoc test, p < 0.01 for each; survival 38, 53, 57, 80%,
respectively).
These experiments show that the expression of high kinase
forms of LRRK2 reduces the proportion flies showing PER, i.e. they
show akinesia.
Rescue of akinesia by L-DOPA and kinase inhibitors
Since the standard symptomatic treatment for PD is L-DOPA, we
tested if this compound would rescue the PER deficit induced by
dopaminergic expression of G2019S or I2020T. In both cases, the
administration of L-DOPA to the adult flies raised the proportion of
flies that respond to sucrose to control levels (Fig. 3a). This was not
due to an increase in general responsiveness, because we saw no
effect of L-DOPA on the flies expressing hLRRK2, KD, or R1441C.
As the most common form of genetic PD is caused by the
LRRK2-G2019S mutation, with its increased kinase activity, a
promising therapy would be to deploy kinase inhibitors targeted
at LRRK2. The first of these to be developed was LRRK2-IN-1.22
Application of 2.5 μM LRRK2-IN-1 partially rescued the frequency
of PER responses, from 32 to 47% (p = 0.002, Fig. 3b). Since LRRK2-
IN-1 has off-target effects, in vitro23,24 and in vivo,6 we next tested
the more specific compound BMPPB-32, which also gave a partial
rescue, to 44% (Fig. 3b). The proportion of flies showing the PER
was the same for LRRK2 and BMPPB-32 (p = 0.077) and both were
below the wild-type level (73%).
We conclude that drugs targeted at LRRK2 ameliorate the
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Fig. 1 The proboscis extension response (PER) of Drosophila. a The
PER takes place when sugar-sensitive (Gr5a) neurons on the legs
respond (step 1) and signal to the sub-esophageal zone of the CNS
(SEZ, step 2). This leads to activation of the E49 motoneurons for the
proboscis extension muscle (step 3), muscle contraction (step 4),
and extension of the proboscis (step 5). In the sub-esophageal zone,
the neuronal signal is modulated by a dopaminergic neuron, TH-
VUM, and by other inputs from CNS neurons, possibly including
other dopaminergic neurons. b Schematic neural circuit, showing
the modulation of the sensory neuron–interneuron–motoneuron
axis by TH-VUM. Other interneurons also modulate the proboscis
extension response, as reviewed recently.17 a Modified after
refs. 52,53; b after refs. 14,15,19
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Dopaminergic expression of LRRK2-G2019S slows movement and
increases tremor in the PER
For TH>G2019S flies showing a PER, recordings were made using a
camera with high frame rate (200 per second), and digitized the
distance from the eye to the end of the proboscis, to measure the
movement during the PER. Individual traces showed that some
TH>G2019S flies had very slow PER, taking three or even four times
longer than the median wild-type control (Fig. 4a), with the
increase in standard error being very noticeable (Fig. 4b). A second
mutant, I2020T, also showed a slower PER (Fig. 4bii). For both
TH>G2019S and TH>I2020T flies, the speed of the PER is fully
rescued to wild type by feeding 2.5 μM BMPPB-32.
Using the independently generated G2019S and hLRRK2 lines,21
we also found a slower PER with TH>G2019S. In this case the
duration of the PER increased from 0.30 ± 0.025 s (TH/+) to 0.57 ±
0.11 s (TH>G2019S) (mean ± SE, Tukey-post-hoc test, p = 0.017).
The TH>hLRRK2 was the same as TH/+ (p = 0.81).
Additionally, it appeared that the TH>G2019S traces were more
irregular. To assess this quantitatively, each trace was fitted by a
smooth curve (a piecewise cubic spline), and the deviation of the
actual trace from smoothed determined (Fig. 4ci). This showed
that the TH>G2019S flies had a much longer “path”, about twice
that of the control flies. The proboscis does not move out in a
smooth trajectory, but oscillates, showing tremor. No such
changes were seen in the TH>hLRRK2 flies; they were the same
as the no-transgene cross (Fig. 4cii).
Thus dopaminergic expression of LRRK2-G2019S induces brady-
kinesia and tremor as well as akinesia.
The single dopamine neuron (TH-VUM) is mainly responsible for
akinesia
Our next step was to test which dopaminergic neurons are
responsible for akinesia in the PER response, focusing on the
difference between flies with increased kinase activity (G2019S or
I2020T) and the kinase dead (KD) line.
There are eight clusters of dopaminergic neurons in the fly CNS
(Fig. 5b), and a range of GAL4 drivers have been developed to
target various subsets of these. We started with a GAL4 driver
DDC,25 which has been widely used for studies of negative
geotaxis and which gives generalized dopaminergic neuron
expression, as well as expressing in serotonergic neurons. As
with the TH-GAL4 (Fig. 1), fewer flies expressing G2019S or I2020T
with DDC showed the PER compared with those flies expressing
LRRK2-KD (Fig. 5). We next tested HL9 (ref. 26) which expresses in
all the dopaminergic neurons except for the PAL cluster (Fig. 5b),
though it may only label a proportion of each cluster. It may also
b
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no significant change with age
for any genotype
Fig. 2 The PER shows bradykinesia with dopaminergic expression of two LRRK2 mutations (G2019S, I2020T) that have increased kinase activity.
This reduces the proportion of flies that respond to sucrose stimulation with a proboscis extension response. a Comparison of the expression
of a Parkinson’s mutant with upregulated kinase activity (LRRK2-G2019S) with wild-type hLRRK2, and a kinase dead line (KD, LRRK2-G2019S-
K1906M). Each group of bars shows the effect of transgene expression in dopaminergic neurons (using the TH-GAL4), the sugar-sensitive
neurons on the legs (Gr5a-GAL4), in the proboscis motoneurons (E49-GAL4) in relation to outcross controls (+) in which no transgene was
expressed. N= 1972, at least 60 flies per sample. b Dopaminergic expression of two increased kinase lines (G2019S, I2020T) reduces the PER at
all ages. There is no decline in the proportion of flies showing PER with age, up to 28 days. N= 1839, at least 75 flies in each sample. cWestern
blot showing that dopaminergic expression of hLRRK2 or KD leads to stronger staining than LRRK2-G2019S, while the R1441C is slightly weaker.
In a and b, wild-type (+) is TH/wa; in c, w− and CS. Data derived from different flies in a and b. In c, flies were raised together, so that the
samples derive from the same experiment and were processed in parallel
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label a few non-dopaminergic neurons (Fig. 5c). Again, the
G2019S and I2020T flies were less responsive than the KD flies.
With the C′-GAL4 line,27 which expresses in all dopaminergic
neurons except the PPM3 and PPL1 clusters, we saw the same
pattern: G2019S and I2020T flies showed less PER than the KD flies.
All these GAL4 lines express in the VUM dopaminergic neurons.
The final GAL4 tested, D′27 expresses in all dopaminergic neurons
except the PAL, PPL2 and does not express strongly in the VUM
neurons. Remarkably, with the D′-GAL4, flies expressing G2019S,
I2020T, and KD forms of LRRK2 all showed an equal response to
sucrose, strikingly different from all the other dopaminergic
GAL4s.
We next used a nuclear GFP (eIfGFP; Fig. 5c) to confirm the
expression pattern of the GAL4 lines in the SEZ. DDC, HL9, and C′,
all showed a group of three GFP-positive neurons located
posteriorly plus a fourth cell anteriorly. One of the three posterior
cells is the unpaired midline TH-VUM and the other two are
descending neurons (left and right DA-DNs), whose activity
represents leg movements.28 The D′>eIfGFP fluorescence pattern
is noticeably different: only the anterior cell shows any GFP signal
(and that weakly), but the three posterior neurons not being
labeled at all. The presence of the three posterior neurons is
confirmed by the anti-TH staining.
Consequently, we suggest that the effect of expressing LRRK2-
G2019S in dopaminergic neurons is mostly mediated by the single
TH-VUM neuron, because the two descending neurons do not
show a direct link to feeding behavior. Only when G2019S is
expressed in the TH-VUM do we see the reduction in PER, i.e.
akinesia. However, we cannot rule out an effect of the PPL2
neurons, which also modulate the feeding system29 as they are
also not targeted by the D′-GAL4.
DISCUSSION
Our principle finding is that expressing LRRK2 forms with
increased kinase activity (G2019S, I2020T) in sets of dopaminergic
neurons that include the TH-VUM is sufficient to induce akinesia,
bradykinesia, and tremor in the fly PER. Although previous work
with flies and rodents have identified movement disorders in PD
models, our PER assay uniquely identifies the components of the
response, in the context of changes mostly due to to a single
dopaminergic neuron (TH-VUM).
A key point is that our PER assay demonstrates dopaminergic-
bradykinesia even at 3 days. In comparison, data from negative
geotaxis (startle-induced climbing response) assays of G2019S,
I2020T, or R1441C transgenics is more complex, depending on age
and genotype. One report shows that while locomotion in
DDC>I2020T flies is already compromised at 5 days,30 another
study shows that TH>I2020T flies show little deficit at any age.31
This may be because DDC-GAL4 includes serotonergic, as well as
dopaminergic neurons, and thus more cells compared with TH-
GAL4. Using DDC-GAL4, to express LRRK2 in old (>5 weeks) flies,
G2019S and R1441C movement is shown to be reduced,32,33 while
younger flies show no deficit. In contrast, our data show
movement deficits in young TH>G2019S and TH>I2020T flies,
which are maintained over the first few weeks of adult life. Indeed,
LRRK2 mutations already start to affect Drosophila larvae,
indicating effects at an earlier timepoint.21,34,35
One disadvantage of working with older flies is that, by 5 weeks,
a proportion of flies will have died, potentially those most strongly
influenced by the transgene, so that negative geotaxis assays may
underestimate the real impact of LRRK2 mutations. Our assay has
the advantage of working at 3 days, before flies have started to
die, and potentially could be developed so that the same
individual fly might be tested at different time points. This would
permit comparison of the individual and population responses.
In our visual assays with TH>G2019S, we found that 3-day-old
flies showed no detectable visual deficits, though younger flies (1-
day-old) had overactive vision, and old flies (28-day-old, or visually
stressed) had much reduced response.6,36,37 Overactivity has also
been reported in young transgenic LRRK2 rats, followed later by
loss of movement.38–40 We have not tested the feeding response
of flies less than 3 days old, because these newly emerged flies
rest and expand their cuticle, and are not feeding: this makes
them unsuitable for PER assay.
However, the PER of our mildly starved 3-day-old TH>G2019S
flies is already reduced, and remains well below wild-type levels
for at least 18 days. A more pronounced PER deficit might arise in
older flies (5 weeks), and/or those kept at 29 °C to enhance
transgene expression.
Further, the movement deficits in our PER assay on flies starved
for 2–3 h are mainly a consequence of expressing G2019S in a
single dopaminergic neuron, TH-VUM, rather than the mixed
effect of a range of dopaminergic clusters.
In this respect the PER assay differs from both negative geotaxis
and our visual assay (three different kinds of dopaminergic neuron
are present in the retina). However, we note that longer term
modulation of feeding appears to involve other dopaminergic
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Fig. 3 L-DOPA and LRRK2-specific kinase inhibitors both rescue the
bradykinesia induced by kinase mutations in the PER. a Feeding
50 μM L-DOPA rescues the reduction in PER by dopaminergic
expression of LRRK2-G2019S or LRRK2-I2020T to wild-type levels.
L-DOPA has no effect on hLRRK2, kinase dead (KD, LRRK2-G2019S-
K1906M) or the GTPase mutant (R1441C). All transgenes expressed by
the TH-GAL4. The wild type (+) is w−. N= 902, at least 60 flies per
sample. b LRRK2 kinase inhibitors rescue the reduction in PER
caused by dopaminergic expression of LRRK2-G2019S. Flies were fed
with either 2.5 μM BMPPB-32 or LRRK2-IN-1. Neither drug affects the
controls or flies with dopaminergic expression of hLRRK2, KD, or
R1441C. Exact genotypes: +/+ CS/w¯; TH/+ TH GAL4/CS. N= 3387, at
least 130 flies per sample
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PER deficit occurs in young flies in which the TH-VUM is still
present, offering the potential to understand the processes by
which LRRK2 leads to neuronal silencing in a single identified
neuron.
We find that both the akinesia and bradykinesia components of
the TH>G2019S effect on PER are dependent on the kinase role of
LRRK2. We observe no effect of expressing the KD (kinase-dead,
G2019S-K1906M) form of LRRK2, although the expression level is
stronger than G2019S. In this respect, it resembles the visual assay,
where expressing G2019S, but not this KD construct led to retinal
neurodegeneration.37 The TH>R1441C flies also showed no
reduction in PER, or in visual degeneration37 though it is possible
that this is because R1441C is not so effectively expressed. The
rescue by the specific LRRK2 inhibitor, BMPPB-32, argues that the
reduction in PER is a consequence of phosphorylation of substrate
(s) by LRRK2. We previously showed this inhibitor was effective in
a visual assay, reverting TH>G2019S phenotypes in both young
and old flies.6,36 Another specific inhibitor LDN-73794 prevents
loss of DDC>G2019S induced locomotion in old flies.42 The PER
assay has an advantage over the climbing assay (startle response),
where degeneration is usually measured at 4–5 weeks, as our flies
only need to be fed with the inhibitors for 3 days, reducing
compound requirements.
Genetically activating or silencing the TH-VUM respectively
increase or decrease the probability of a PER.14 Thus, our data
showing kinase active LRRK2 transgenes in the TH-VUM reduce
PER could be explained by a reduction in dopamine release by this
neuron. We hypothesize that expressing G2019S in the TH-VUM
could lead to either (i) failure of TH-VUM neurites to grow, (ii) a
reduction in its tonic firing, (iii) less dopamine synthesis, or (iv)
lower probability of release of dopamine onto the reflex pathway.
Cultured mammalian neurons, fly motoneurons, and sensory cells
all have reduced neurites with G2019S.23,43,44 While it is possible
that G2019S also reduces neuritic branching in the TH-VUM
neuron, our data rather favor hypotheses (iii) or (iv) since we found
that feeding flies L-DOPA rescued the TH>G2019S loss of PER.
Reduced dopamine levels have been reported with DDC>G2019S,
and with ubiquitous expression of an increased kinase form of the
fly homolog dLRRK.45,46 In both Drosophila and mammals, L-DOPA
can cross the blood–brain barrier, but dopamine cannot.47 Thus
we suggest that uptake of L-DOPA into the TH-VUM leads to
increased dopamine levels and release, rescuing the effect of
TH>G2019S. Increasing the amount of dopamine released onto the
sugar-sensing Gr5a neurons would then rescue the proportion of
flies that show the PER (akinesia), while release onto second order,
local interneurons, might affect the motoneurons and thence
speed (bradykinesia), and tremor of the proboscis extension. Such
a dual output onto Gr5a neurons and onto local interneurons is
suggested by the fact that 2.5 μM BMPPB-32 fully rescues
bradykinesia, but only partially rescues akinesia. Although a
number of interneurons in the SEZ with roles controlling proboscis
extension, ingestion, and memory have recently been identified
(e.g. see refs. 48–50), the link between Gr5a sense cells and the E49
motoneurons remains to be established.
METHODS
Flies, Drosophila melanogaster, were raised at 25 °C on cornmeal-sugar-
agar-yeast food. The following GAL4 lines were used: TH (tyrosine
hydoxylase) GAL4,51 DDC-GAL4,25 HL9,26 or the C′ and D′-GAL4 stocks,27
the pan-neuronal nSyb-GAL4 (Stephen Goodwin), the sensory Gr5a-GAL4
and motoneuron E49-GAL4.18 The UAS lines were: wild-type hLRRK2 or
LRRK2-G2019S,32 hLRRK2-I2020T and the kinase dead line LRRK2-G2019S-
K1906M (hereafter, KD),21 and hLRRK2-R1441C;31 eIfGFP (eIF4AIII::GFP,
Andreas Prokop). In some confirmatory experiments, independent LRRK2-
G2019S and hLRRK2 lines were used.21 The lab stocks of CS (Canton-S),
w1118 (w¯), and wapricot (wa Bloomington stock 148) provided “wild-type”
outcross controls.
PER was performed (A.C.C.) by collecting male flies of known age at the
start of the working day, under CO2 anesthesia, and sticking them ventral
side up to card with rubber cement (Fixo Gum). Flies were left to recover
for 2–3 h at 25 °C. They were presented with a droplet of 100mM sucrose
solution to the legs, and the immediate PER/no PER scored (response in <2
s). Experiments were designed so that each graph plotted here comes from
flies scored over three adjacent days, with the genotypes mixed each day,
to allow for the small variations in food and environmental conditions.
Fig. 4 Dopaminergic expression of LRRK2-G2019S (TH GAL4) slows and increases tremor in the PER. a The raw plot of the distance between the
eye and the tip of the proboscis shows that the PER takes longer, and is more variable, with TH>G2019S than with TH>hLRRK2 or the control
with no transgene expressed (TH/+). b Summary showing the longer (and more variable) time taken by the PER in TH>G2019S and TH>I2020T
flies. Feeding 2.5 μM BMPPB-32 reverts the time taken to control levels. c Fitting a piecewise cubic spline to each trace (i) generates a smooth
curve, allowing the calculation of the extra path taken by the proboscis. The mean extra path (ii) is longer for TH>G2019S than the wild type or
TH>hLRRK2, indicating increased tremor. Data for a, bi, and c from the same data set, N= 80, at least 26 in each group; for bii N= 141, at least
15 in each group. TH/+ is TH/w¯
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Power calculations indicate that a “medium” effect size, with a sample of
500 flies, and 16 df, would be detected at the 1 % level >98% of the time.
Drugs were fed to adult flies from eclosion until testing. L-DOPA (Sigma)
was added to food (final concentration 50 μM). BMPPB-32 and LRRK2-IN-1
(Lundbeck) were dissolved to give a final concentration in the food at
2.5 μM.
PER was filmed using a Mikrotron MC-1362 camera mounted on a Zeiss
Stemi microscope. Videos were acquired at 200 frames/s; sample movies
for a wild type and TH>G2019S flies are presented in Movies S1 and S2.
Only the first PER of each fly was analyzed. In Matlab, the eye and tip of the
proboscis were marked and their separation was determined for each
frame individually. The analyses of Movies S1 and S2 are shown in
Movies S3 and S4, respectively.
Western blots were performed as described6 using the heads of 3-day-
old female flies, raised at 29 °C using anti-LRRK2 (Neuromab, clone N241A/
34, 1:1000) and anti-β-actin (Proteintech, 1:180,000, loading control). The
data are representative of three blots.
Immunocytochemistry was as described recently,37 using mouse anti-TH
(Immunostar, 1:1000) and driving eIfGFP using the required GAL4 line. All
data are from male flies, aged 3–5 days. No anti-GFP was used in the data
chosen for illustration. The brightness and contrast of the images was
adjusted in ImageJ so that the cells could be seen in both color channels,
as each GAL4 drove GFP with a different intensity in the VUM neurons.
Original images available on request to cje2@york.ac.uk Representative
data from at least three preparations are shown.
Statistics
For analysis of the proportion of flies showing a PER, statistical significance
was determined using the χ2-post-hoc test in the “Fifer” package of R.
Confidence limits were determined using the Binomial test in R.
Measurements of the speed of the PER were analyzed by ANOVA and
Tukey post-hoc tests. For a “medium” effect size, with 26 flies in each of
three samples, and the probability of 0.05, the power is 63%. N values for
each genotype/treatment are included in Supplementary Table 1.
Data availability statement
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
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Fig. 5 The presence of dopaminergic TH-VUM neuron is essential for the G2019S/I2020T-mediated reduction in PER. a Proportion of flies
responding when LRRK2 transgenes are expressed in different subsets of the dopaminergic neurons, using the DDC, HL9, C′ or D′ GAL4 drivers.
There is no difference between the increased kinase mutants (G2019S/I2020T) and the kinase-dead construct (KD, G2019S-K1906M) with the D′
GAL4, which does not express in the TH-VUM neurons. All the other GAL4 lines tested express in the TH-VUM neurons and show a smaller
response in G2019S/I2020T than in KD. Exact genotypes: + is wa. b Summary maps of the expression patterns of the GAL4 drivers used in a.
Figures redrawn after Mao and Davis (2009).10 c The lack of TH-VUM in the D′ line is confirmed anatomically. Each panel shows the projection
of a confocal stack through the sub-esophageal zone (as marked in the first panel by the dotted box). Neurons marked by expression of eIfGFP
under the control of the relevant GAL4 and stained by anti-TH antibody. The SEZ contains a single anterior cell (“a”) and a group of three
posterior cells (“p”), marked with anti-TH antibody With DDC, HL9, and C′ GAL4 drivers, all four SEZ neurons were GFP positive. With D′, the
nucleus of the anterior neuron “a” has a weak GFP signal, but the three posterior neurons marked with anti-TH antibody do not fluoresce
green (note the cytoplasm of the two left posterior cells is merged in this projection of the z-stack, but their empty nuclei are still visible).
Scalebar 20 μm
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